Replies to post #103015 on Biotech Values

[DewDiligence]

Ipsen’s 3Q10 worldwide sales of Dysport rose 22% YoY and 9% QoQ to $71M (€51.8M), but US sales in non-cosmetic indications were de minimis:

http://finance.yahoo.com/news/Ipsens-First-Nine-Months-of-bw-560199592.html?x=0&.v=1

Worldwide in all indications combined, AGN’s Botox outsells Dysport by about 8:1.